Phase 3 Study of Immunotherapy to Treat Advanced Prostate Cancer

Clinical Trial ID NCT01057810

PubWeight™ 72.53‹?›

🔗 Visit the page for NCT01057810

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol 2014 5.89
2 Ipilimumab alone or in combination with radiotherapy in metastatic castration-resistant prostate cancer: results from an open-label, multicenter phase I/II study. Ann Oncol 2013 2.35
3 Circulating tumor cells as biomarkers in prostate cancer. Clin Cancer Res 2011 2.17
4 Antibody-based therapeutics to watch in 2011. MAbs 2011 2.00
5 Novel therapies for metastatic castrate-resistant prostate cancer. J Natl Cancer Inst 2011 1.98
6 End points and outcomes in castration-resistant prostate cancer: from clinical trials to clinical practice. J Clin Oncol 2011 1.94
7 CTLA-4 blockade in tumor models: an overview of preclinical and translational research. Cancer Immun 2013 1.71
8 Biomarkers in the management and treatment of men with metastatic castration-resistant prostate cancer. Eur Urol 2011 1.64
9 The changing therapeutic landscape of castration-resistant prostate cancer. Nat Rev Clin Oncol 2011 1.55
10 Castration-resistant prostate cancer: mechanisms, targets, and treatment. Prostate Cancer 2012 1.47
11 Immunotherapy for the treatment of prostate cancer. Nat Rev Clin Oncol 2011 1.12
12 Overview of the latest treatments for castration-resistant prostate cancer. Nat Rev Urol 2013 1.12
13 Prostate cancer immunotherapy. Clin Cancer Res 2011 1.11
14 Castration-resistant prostate cancer: latest evidence and therapeutic implications. Ther Adv Med Oncol 2014 1.11
15 Diversity of antigen-specific responses induced in vivo with CTLA-4 blockade in prostate cancer patients. J Immunol 2012 1.09
16 Current status of immunological therapies for prostate cancer. Curr Opin Urol 2010 1.06
17 Emerging novel therapies in the treatment of castrate-resistant prostate cancer. Can Urol Assoc J 2011 1.04
18 Molecular pathways and targets in prostate cancer. Oncotarget 2014 1.00
19 Clinical impact of checkpoint inhibitors as novel cancer therapies. Drugs 2014 0.99
20 Immune Infiltration and Prostate Cancer. Front Oncol 2015 0.98
21 The changing landscape in the treatment of metastatic castration-resistant prostate cancer. Ther Adv Med Oncol 2013 0.97
22 Endpoints, patient selection, and biomarkers in the design of clinical trials for cancer vaccines. Cancer Immunol Immunother 2011 0.97
23 Sequential use of novel therapeutics in advanced prostate cancer following docetaxel chemotherapy. Ther Adv Urol 2014 0.96
24 Cancer immunotherapy: a paradigm shift for prostate cancer treatment. Nat Rev Urol 2012 0.93
25 Phase I trial of tremelimumab in combination with short-term androgen deprivation in patients with PSA-recurrent prostate cancer. Cancer Immunol Immunother 2011 0.93
26 Sequencing CTLA-4 blockade with cell-based immunotherapy for prostate cancer. J Transl Med 2013 0.93
27 Emerging therapeutic approaches in the management of metastatic castration-resistant prostate cancer. Prostate Cancer Prostatic Dis 2011 0.93
28 Combining immunological and androgen-directed approaches: an emerging concept in prostate cancer immunotherapy. Curr Opin Oncol 2012 0.92
29 Metastatic castration-resistant prostate cancer: new therapies, novel combination strategies and implications for immunotherapy. Oncogene 2013 0.91
30 Exploiting synergy: immune-based combinations in the treatment of prostate cancer. Front Oncol 2014 0.91
31 Immunotherapy for prostate cancer: recent developments and future challenges. Cancer Metastasis Rev 2014 0.90
32 Novel therapeutic strategies for metastatic prostate cancer in the post-docetaxel setting. Oncologist 2011 0.90
33 Unmasking the immune recognition of prostate cancer with CTLA4 blockade. Nat Rev Cancer 2012 0.89
34 Polysaccharide-K augments docetaxel-induced tumor suppression and antitumor immune response in an immunocompetent murine model of human prostate cancer. Int J Oncol 2011 0.88
35 Recent progress in pharmaceutical therapies for castration-resistant prostate cancer. Int J Mol Sci 2013 0.88
36 Cell mates: paracrine and stromal targets for prostate cancer therapy. Nat Rev Urol 2013 0.87
37 Therapeutic vaccines as a promising treatment modality against prostate cancer: rationale and recent advances. Ther Adv Vaccines 2014 0.86
38 Time to disease-related pain and first opioid use in patients with metastatic castration-resistant prostate cancer treated with sipuleucel-T. Prostate Cancer Prostatic Dis 2014 0.86
39 Blocking immune checkpoints in prostate, kidney, and urothelial cancer: An overview. Urol Oncol 2016 0.86
40 Demystifying immunotherapy in prostate cancer: understanding current and future treatment strategies. Cancer J 2013 0.84
41 Immunotherapy and therapeutic vaccines in prostate cancer: an update on current strategies and clinical implications. Asian J Androl 2014 0.84
42 Immunotherapy in prostate cancer: emerging strategies against a formidable foe. Vaccine 2011 0.84
43 Emerging molecularly targeted therapies in castration refractory prostate cancer. Prostate Cancer 2013 0.83
44 The current and emerging role of immunotherapy in prostate cancer. Clin Genitourin Cancer 2010 0.83
45 Steroid responsive encephalopathy associated with autoimmune thyroiditis following ipilimumab therapy: a case report. BMC Res Notes 2015 0.83
46 Emerging targeted therapies for castration-resistant prostate cancer. Front Endocrinol (Lausanne) 2012 0.81
47 The Evolving Role of Immune Checkpoint Inhibitors in Cancer Treatment. Oncologist 2015 0.81
48 Current status of immunological approaches for the treatment of prostate cancer. Curr Opin Urol 2012 0.81
49 Advanced prostate cancer - patient survival and potential impact of enzalutamide and other emerging therapies. Ther Clin Risk Manag 2014 0.80
50 Safety and efficacy of cabazitaxel in the docetaxel-treated patients with hormone-refractory prostate cancer. Clin Med Insights Oncol 2012 0.80
51 Beyond sipuleucel-T: immune approaches to treating prostate cancer. Curr Treat Options Oncol 2014 0.79
52 Ipilimumab. Drugs R D 2010 0.79
53 Unmet needs in the prediction and detection of metastases in prostate cancer. Oncologist 2013 0.78
54 Sipuleucel-T for therapy of asymptomatic or minimally symptomatic, castrate-refractory prostate cancer: an update and perspective among other treatments. Onco Targets Ther 2011 0.78
55 Current and emerging treatment options for castration-resistant prostate cancer: a focus on immunotherapy. J Clin Immunol 2011 0.78
56 A changing landscape in castration-resistant prostate cancer treatment. Front Endocrinol (Lausanne) 2012 0.78
57 Visceral metastases and prostate cancer treatment: 'die hard,' 'tough neighborhoods,' or 'evil humors'? Oncology (Williston Park) 2014 0.78
58 Androgen pathway resistance in prostate cancer and therapeutic implications. Expert Opin Pharmacother 2015 0.77
59 Immunotherapy for prostate cancer enters its golden age. Clin Med Insights Oncol 2012 0.77
60 Prognostic and predictive value of plasma testosterone levels in patients receiving first-line chemotherapy for metastatic castrate-resistant prostate cancer. Br J Cancer 2014 0.77
61 Immune Therapy for Prostate Cancer. Cancer J 2016 0.76
62 Ipilimumab: a potential immunologic agent in the treatment of metastatic castration-resistant prostate cancer. Cancer Biol Ther 2014 0.76
63 Immune Checkpoint Inhibitors and Prostate Cancer: A New Frontier? Oncol Rev 2016 0.76
64 Immunotherapy in genitourinary malignancies. Curr Opin Urol 2016 0.75
65 Management of metastatic castration-resistant prostate cancer. Eur Urol Rev 2011 0.75
66 The changing landscape of treatment options for metastatic castrate-resistant prostate cancer: challenges and solutions for physicians and patients. P T 2012 0.75
67 Exciting Therapies Ahead in Prostate Cancer. P T 2015 0.75
68 Is there a role for immune checkpoint blockade with ipilimumab in prostate cancer? Cancer Med 2013 0.75
69 Immune Checkpoint Therapies in Prostate Cancer. Cancer J 2016 0.75
70 Drugs that offer a survival advantage for men with bone metastases resulting from castration-resistant prostate cancer: new and emerging treatment options. P T 2014 0.75
Next 100